<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">16953653</PMID>
      <DateCompleted>
        <Year>2006</Year>
        <Month>11</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1172-7047</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>20</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2006</Year>
            </PubDate>
          </JournalIssue>
          <Title>CNS drugs</Title>
          <ISOAbbreviation>CNS Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rufinamide.</ArticleTitle>
        <Pagination>
          <StartPage>751</StartPage>
          <EndPage>761</EndPage>
          <MedlinePgn>751-60; discussion 761</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures associated with treatment-resistant Lennox-Gastaut syndrome in a well designed 16-week trial. Rufinamide recipients experienced significantly greater reductions from baseline than placebo recipients in the median frequency of total seizures and tonic-atonic seizures per 28 days and demonstrated improvements in seizure severity. Furthermore, these beneficial effects of rufinamide on seizure frequency were maintained throughout a subsequent 3-year, open-label extension study. Relative to placebo, adjunctive rufinamide significantly reduced the frequency of partial seizures per 28 days in adult patients with inadequately controlled partial seizures in two well designed trials of approximate, equals3 months duration, with a higher proportion of rufinamide recipients achieving a reduction of &gt;or=50% in partial seizure frequency per 28 days. Rufinamide was generally well tolerated in patients with Lennox-Gastaut syndrome and in those with partial seizures, with adverse events being mostly mild or moderate in severity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Deeks</LastName>
            <ForeName>Emma D</ForeName>
            <Initials>ED</Initials>
            <AffiliationInfo>
              <Affiliation>Adis International Limited, Auckland, New Zealand. demail@adis.co.nz</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scott</LastName>
            <ForeName>Lesley J</ForeName>
            <Initials>LJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D023362">Evaluation Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>CNS Drugs</MedlineTA>
        <NlmUniqueID>9431220</NlmUniqueID>
        <ISSNLinking>1172-7047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WFW942PR79</RegistryNumber>
          <NameOfSubstance UI="C079703">rufinamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>30</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2006</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2006</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2006</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16953653</ArticleId>
        <ArticleId IdType="doi">10.2165/00023210-200620090-00007</ArticleId>
        <ArticleId IdType="pii">2097</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Expert Opin Investig Drugs. 2000 Apr;9(4):829-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11060713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Child Neurol. 2002 Jan;17 Suppl 1:S70-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11918467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharm Res. 1995 Dec;12(12):1878-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8786960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epilepsia. 2006 Jul;47(7):1153-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16886978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cochrane Database Syst Rev. 2003;(3):CD003277</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12917958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2004 Mar 4;350(10):1013-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14999113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biopharm Drug Dispos. 1998 May;19(4):259-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9604126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epilepsy Res. 2001 Feb;43(2):115-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11164700</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
